SG190406A1 - Formulations comprising methylthioninium chloride - Google Patents
Formulations comprising methylthioninium chloride Download PDFInfo
- Publication number
- SG190406A1 SG190406A1 SG2013040357A SG2013040357A SG190406A1 SG 190406 A1 SG190406 A1 SG 190406A1 SG 2013040357 A SG2013040357 A SG 2013040357A SG 2013040357 A SG2013040357 A SG 2013040357A SG 190406 A1 SG190406 A1 SG 190406A1
- Authority
- SG
- Singapore
- Prior art keywords
- mtc
- composition
- tablets
- diluent
- direct compression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41816410P | 2010-11-30 | 2010-11-30 | |
| PCT/GB2011/001662 WO2012072977A2 (en) | 2010-11-30 | 2011-11-30 | Compound formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG190406A1 true SG190406A1 (en) | 2013-06-28 |
Family
ID=45418703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013040357A SG190406A1 (en) | 2010-11-30 | 2011-11-30 | Formulations comprising methylthioninium chloride |
| SG10201602111VA SG10201602111VA (en) | 2010-11-30 | 2011-11-30 | Formulations Comprising Methylthioninium Chloride |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201602111VA SG10201602111VA (en) | 2010-11-30 | 2011-11-30 | Formulations Comprising Methylthioninium Chloride |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9192611B2 (https=) |
| EP (1) | EP2645994B1 (https=) |
| JP (1) | JP6093707B2 (https=) |
| CN (1) | CN103379901B (https=) |
| AU (1) | AU2011334679B2 (https=) |
| CA (1) | CA2818068C (https=) |
| ES (1) | ES2655492T3 (https=) |
| MY (1) | MY163074A (https=) |
| SG (2) | SG190406A1 (https=) |
| WO (1) | WO2012072977A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014153444A (ja) * | 2013-02-06 | 2014-08-25 | Konica Minolta Inc | 位相差フィルム、偏光板及び液晶表示装置 |
| KR102592614B1 (ko) | 2016-07-25 | 2023-10-24 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| FR3104438B1 (fr) | 2019-12-12 | 2021-11-19 | Univ Bordeaux | Formulation pour le bleu de methylene et procede |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| AU2023346900A1 (en) | 2022-09-21 | 2025-04-10 | TauRx Therapeutics Management Ltd | Novel formulations and vehicles |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880373A (en) | 1988-04-28 | 1989-11-14 | The Upjohn Company | Tablet press |
| JPH0840942A (ja) * | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | 薬物放出制御製剤 |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| AU2005286235C1 (en) | 2004-09-23 | 2013-08-22 | TauRx Therapeutics Management Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC) |
| ATE415148T1 (de) * | 2004-10-19 | 2008-12-15 | Krka Tovarna Zdravil D D Novo | Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid |
| AU2006283121A1 (en) * | 2005-08-24 | 2007-03-01 | Wyeth | Bazedoxifene acetate formulations and manufacturing process thereof |
| DE602006006536D1 (de) * | 2006-01-05 | 2009-06-10 | Teva Pharma | Trockene Aripiprazolformulierungen |
| EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| US20080317678A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
| CA3027974C (en) | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| EP2227766A2 (en) | 2007-11-05 | 2010-09-15 | Wista Laboratories Ltd. | Systems for clinical trials |
| PL2480540T3 (pl) * | 2009-09-24 | 2018-05-30 | Wista Laboratories Ltd. | Pentahydrat chlorku metylotioninowego, jego wytwarzanie i zastosowanie farmaceutyczne |
-
2011
- 2011-11-30 US US13/989,953 patent/US9192611B2/en active Active
- 2011-11-30 SG SG2013040357A patent/SG190406A1/en unknown
- 2011-11-30 CA CA2818068A patent/CA2818068C/en active Active
- 2011-11-30 JP JP2013541414A patent/JP6093707B2/ja active Active
- 2011-11-30 ES ES11802119.5T patent/ES2655492T3/es active Active
- 2011-11-30 WO PCT/GB2011/001662 patent/WO2012072977A2/en not_active Ceased
- 2011-11-30 EP EP11802119.5A patent/EP2645994B1/en active Active
- 2011-11-30 MY MYPI2013001934A patent/MY163074A/en unknown
- 2011-11-30 AU AU2011334679A patent/AU2011334679B2/en active Active
- 2011-11-30 SG SG10201602111VA patent/SG10201602111VA/en unknown
- 2011-11-30 CN CN201180057700.9A patent/CN103379901B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2818068C (en) | 2019-06-11 |
| WO2012072977A3 (en) | 2012-08-16 |
| WO2012072977A8 (en) | 2012-09-20 |
| CN103379901A (zh) | 2013-10-30 |
| JP6093707B2 (ja) | 2017-03-08 |
| JP2013544272A (ja) | 2013-12-12 |
| AU2011334679A1 (en) | 2013-07-18 |
| CA2818068A1 (en) | 2012-06-07 |
| AU2011334679B2 (en) | 2016-12-15 |
| SG10201602111VA (en) | 2016-04-28 |
| US9192611B2 (en) | 2015-11-24 |
| US20130243858A1 (en) | 2013-09-19 |
| MY163074A (en) | 2017-08-15 |
| ES2655492T3 (es) | 2018-02-20 |
| CN103379901B (zh) | 2018-04-03 |
| WO2012072977A2 (en) | 2012-06-07 |
| EP2645994A2 (en) | 2013-10-09 |
| EP2645994B1 (en) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3024442B1 (en) | Formulations containing amorphous dapagliflozin | |
| AU2015215000B2 (en) | Solid pharmaceutical compositions of androgen receptor antagonists | |
| WO2008027600A2 (en) | Imatinib compositions | |
| CA2818068C (en) | Formulations comprising methylthioninium chloride | |
| AU2019232937B2 (en) | Ceritinib formulation | |
| WO2013097003A1 (pt) | Composição farmacêutica sólida compreendendo antibiótico da família das quinolonas e processo de sua obtenção | |
| CN103372014A (zh) | 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法 | |
| EP2524688B1 (en) | Composition for modified release comprising ranolazine | |
| EP4183390A1 (en) | An orodispersible pharmaceutical dosage form of edoxaban | |
| JP5103173B2 (ja) | ジヒドロピリジン系化合物の分解を防止する方法 | |
| WO2020111089A1 (ja) | 医薬組成物 | |
| US20240374527A1 (en) | Pharmaceutical Composition Comprising Lumateperone | |
| EP3875081B1 (en) | Pharmaceutical composition containing alkyl carbamoyl naphthalenyloxy octenoyl hydroxyamide phosphate, tartrate or combination thereof, and preparation method therefor | |
| KR20190050784A (ko) | 테소펜신 조성물 | |
| HK1184386B (en) | Formulations comprising methylthioninium chloride | |
| HK1184386A (en) | Formulations comprising methylthioninium chloride | |
| CN112057427A (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
| BRPI0621739A2 (pt) | formulação estável que consiste em drogas sensìveis à umectação e seu procedimento de fabricação | |
| KR20250136432A (ko) | 밀벡시안 제약 조성물 | |
| KR20250022143A (ko) | 피미테스핍을 함유하는 의약 조성물 | |
| JP2021104939A (ja) | ラメルテオンを含む錠剤および医薬組成物 | |
| BR112019020269A2 (pt) | formulação farmacêutica | |
| BR112019020269B1 (pt) | Dispersão sólida, composição farmacêutica, seus usos e seus métodos de preparação | |
| HK1229715A1 (en) | Ceritinib formulation | |
| HK1229715B (en) | Ceritinib formulation |